| 2026-08-11 | Press release | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-08-05 | Press release | Press Release |
| 2026-08-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-05 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-29 | Press release | Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026 |
| 2026-07-10 | Press release | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-01 | Deck | Download PDF file, (opens in new window) |
| 2026-06-18 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-14 | Press release | Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibro |
| 2026-06-11 | Press release | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-04 | Press release | Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans P |
| 2026-05-30 | Press release | Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Cong |
| 2026-05-18 | 8-K | Form 8-K, Item 1.01 |
| 2026-05-12 | Press release | Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible |
| 2026-05-11 | Press release | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-06 | Press release | Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update |
| 2026-05-06 | Press release | Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 |
| 2026-05-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-06 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-04 | Press release | Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Ch |
| 2026-05-04 | Press release | Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with |
| 2026-05-04 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-03 | Deck | VISTAS Phase 2b Topline Results AZURE-1 Phase 2b Topline Results |
| 2026-04-27 | Press release | Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic H |
| 2026-04-27 | 8-K | Form 8-K, Item 8.01 |
| 2026-04-23 | Proxy | Definitive proxy statement |
| 2026-04-10 | Press release | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-04-08 | 8-K | Form 8-K/A, Item 9.01 |
| 2026-03-16 | Press release | Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholest |
| 2026-03-11 | Press release | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-05 | Press release | Mirum Pharmaceuticals Completes AZURE-1 Enrollment and AZURE-4 Screening in Phase 3 Program of brelovitug in Chronic Hep |
| 2026-02-26 | Transcript | Q4 FY25 earnings call transcript |
| 2026-02-25 | Press release | Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on Februar |
| 2026-02-25 | Press release | Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update |
| 2026-02-25 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-25 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-23 | Press release | Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 2026-02-10 | Press release | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-01-26 | Press release | Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease |
| 2026-01-26 | 8-K | Form 8-K, Item 2.01 |